日本妊娠早期使用头孢地酮酯安全性的系列案例研究

IF 1.3 4区医学 Q3 PEDIATRICS Congenital Anomalies Pub Date : 2024-12-01 DOI:10.1111/cga.12588

Mariko Honma, Naoto Suzuki, Mikako Goto, Taku Obara, Yoshiyuki Saito, Ken Nakajima, Ritsuko Yamane, Kunihiko Takahashi, Takeo Nakayama, Masahiro Hayashi, Atsuko Murashima, Akira Toyama

{"title":"日本妊娠早期使用头孢地酮酯安全性的系列案例研究","authors":"Mariko Honma, Naoto Suzuki, Mikako Goto, Taku Obara, Yoshiyuki Saito, Ken Nakajima, Ritsuko Yamane, Kunihiko Takahashi, Takeo Nakayama, Masahiro Hayashi, Atsuko Murashima, Akira Toyama","doi":"10.1111/cga.12588","DOIUrl":null,"url":null,"abstract":"<p>We evaluated the teratogenic risk associated with exposure to cefditoren pivoxil during the first trimester of pregnancy using the integrated databases of the Toranomon Hospital and the National Center for Child Health and Development. Among 13 599 registered individuals, the analysis included 285 subjects who had taken cefditoren pivoxil during the first trimester of pregnancy. The rates of stillbirth, miscarriage, and elective terminations were 0.4%, 5.6%, and 2.1%, respectively. Among 262 live births, the rates of preterm birth, low birth weight, and major congenital malformations were 4.6%, 5.7%, and 1.2%, respectively. Our results suggest that exposure to cefditoren pivoxil during the first trimester of pregnancy does not significantly increase the risk of adverse pregnancy outcomes and infant outcomes.</p>","PeriodicalId":10626,"journal":{"name":"Congenital Anomalies","volume":"65 1","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A case series study on the safety of cefditoren pivoxil use during the first trimester of pregnancy in Japan\",\"authors\":\"Mariko Honma, Naoto Suzuki, Mikako Goto, Taku Obara, Yoshiyuki Saito, Ken Nakajima, Ritsuko Yamane, Kunihiko Takahashi, Takeo Nakayama, Masahiro Hayashi, Atsuko Murashima, Akira Toyama\",\"doi\":\"10.1111/cga.12588\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>We evaluated the teratogenic risk associated with exposure to cefditoren pivoxil during the first trimester of pregnancy using the integrated databases of the Toranomon Hospital and the National Center for Child Health and Development. Among 13 599 registered individuals, the analysis included 285 subjects who had taken cefditoren pivoxil during the first trimester of pregnancy. The rates of stillbirth, miscarriage, and elective terminations were 0.4%, 5.6%, and 2.1%, respectively. Among 262 live births, the rates of preterm birth, low birth weight, and major congenital malformations were 4.6%, 5.7%, and 1.2%, respectively. Our results suggest that exposure to cefditoren pivoxil during the first trimester of pregnancy does not significantly increase the risk of adverse pregnancy outcomes and infant outcomes.</p>\",\"PeriodicalId\":10626,\"journal\":{\"name\":\"Congenital Anomalies\",\"volume\":\"65 1\",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Congenital Anomalies\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cga.12588\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Congenital Anomalies","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cga.12588","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

摘要

我们利用Toranomon医院和国家儿童健康与发展中心的综合数据库，评估了妊娠前三个月暴露于头孢地托伦酯的致畸风险。在13599名登记的个体中，分析包括285名在怀孕前三个月服用头孢地托林酯的受试者。死产、流产和选择性终止妊娠的发生率分别为0.4%、5.6%和2.1%。262例活产婴儿中，早产率为4.6%，低出生体重率为5.7%，重大先天性畸形率为1.2%。我们的研究结果表明，在怀孕的前三个月接触头孢地托伦酯不会显著增加不良妊娠结局和婴儿结局的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

A case series study on the safety of cefditoren pivoxil use during the first trimester of pregnancy in Japan

We evaluated the teratogenic risk associated with exposure to cefditoren pivoxil during the first trimester of pregnancy using the integrated databases of the Toranomon Hospital and the National Center for Child Health and Development. Among 13 599 registered individuals, the analysis included 285 subjects who had taken cefditoren pivoxil during the first trimester of pregnancy. The rates of stillbirth, miscarriage, and elective terminations were 0.4%, 5.6%, and 2.1%, respectively. Among 262 live births, the rates of preterm birth, low birth weight, and major congenital malformations were 4.6%, 5.7%, and 1.2%, respectively. Our results suggest that exposure to cefditoren pivoxil during the first trimester of pregnancy does not significantly increase the risk of adverse pregnancy outcomes and infant outcomes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Congenital Anomalies PEDIATRICS-

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Congenital Anomalies is the official English language journal of the Japanese Teratology Society, and publishes original articles in laboratory as well as clinical research in all areas of abnormal development and related fields, from all over the world. Although contributions by members of the teratology societies affiliated with The International Federation of Teratology Societies are given priority, contributions from non-members are welcomed.